Imipenem + Cilastatin Aptapharma (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, preventing peptidoglycan cross‑linking and causing cell lysis. Cilastatin, co‑formulated, blocks renal dehydropeptidase I, protecting imipenem from enzymatic degradation and extending its antibacterial activity.

The dosing regimen for Imipenem + Cilastatin Aptapharma is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. No fixed dose is provided here; the prescriber sets the appropriate regimen.

Safety data for Imipenem + Cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should evaluate each case individually and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Imipenem combined with cilastatin offers a broad spectrum of activity against Gram‑positive, Gram‑negative and anaerobic bacteria, similar to other carbapenems like meropenem or ertapenem. The addition of cilastatin protects imipenem from renal degradation, potentially allowing higher plasma concentrations. Choice among carbapenems often depends on local resistance patterns, dosing convenience, and specific infection sites.

Imipenem + Cilastatin Aptapharma should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Once reconstituted, use according to the manufacturer’s stability guidelines and discard any unused portion after the recommended time.

The medication is supplied as a sterile injection solution for intravenous infusion. It is administered by a healthcare professional via a peripheral or central IV line, typically over a set infusion time as directed by the prescriber. Dilution and infusion rates are based on the prescribed dose and patient-specific factors.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and severe allergic reactions such as anaphylaxis. Rare but life‑threatening skin reactions like Stevens‑Johnson syndrome may also occur. Prompt recognition and discontinuation are essential if these events arise.

Patients with a known hypersensitivity to imipenem, cilastatin, or any β‑lactam antibiotics should avoid this product. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, as drug interactions may reduce valproate levels.